ArticleMolecular oncology2023

Activation of the EGFR/PI3K/AKT pathway limits the efficacy of trametinib treatment in head and neck cancer.

Ofra Novoplansky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.